Advancing Translational Research in Alzheimer’s Disease https://t.co/HpIirDNNSp via @Inside_PM Very exciting developments in the Alzheimer’s disease field @AlamarBio@BillGates
We are thrilled to partner with @EsyaLabs . The integration of @AlamarBios novel #NULISA biomarker assays into their multi-omics platform will advance the field of testing for neurodegeneration diseases. https://t.co/OLBIRiiyyW
Benchmarking of a multi‐biomarker low‐volume panel for Alzheimer's disease and related dementia research - Ibanez - Alzheimer's & Dementia - Wiley Online Library https://t.co/z5hcUDmGx8
Truly game changing technology from @AlamarBio
Our friends and partners at @AlamarBio explain how their highly sensitive and multiplexed profiling technology can support and boost the field’s aging biomarker R&D programs.
This meeting is going to be so interesting. @AlamarBio will be showcasing data showing how ultra-sensitive protein biomarkers can be used to calculate biological age.
🌟 2024 Biomarkers of Aging Conference Speaker Highlight 🌟
Dr. Ma is the CTO of Alamar Biosciences (@AlamarBio), a life science tools company developing next-generation proteomic technologies for liquid biopsies. His work focuses on innovation in biomarker technologies such as RNAscope and NULISA, and he also has extensive experience in applying novel technologies to biomarker discovery and diagnostic assay development.
Join us on November 1-2 at Harvard Medical School for the 2024 Biomarkers of Aging Conference, where Dr. Ma and other pioneers in longevity will present cutting-edge research on reliable biomarkers of aging for longevity interventions.
Ticket sales end in just a few days on October 21st, so be sure to secure your tickets soon! https://t.co/n9G3EBGis6